慢性髓系白血病TKI治疗新目标——无治疗缓解

A New Goal for Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia:Treatment-free Remission

BCR/ABL酪氨酸激酶抑制剂(TKI)显著改变了慢性髓系白血病(CML)患者的生存及预后。长期服用TKI药物常常伴随着沉重的经济负担和发生慢性不良反应的风险。目前,无治疗缓解(treatment-free remission,TFR)逐渐被视为CM L治疗研究的新目标。临床试验报道,伊马替尼治疗后获得深层分子学反应的患者,在停止TKI治疗后仍然可以维持分子学缓解。本文结合TKI停药临床试验数据及最新研究进展,对CM L患者能否治愈和如何把握安全的停药策略等问题作一综述。当然,CML获得彻底的治愈,还需更多停药试验予以进一步研究。

Tyrosine kinase inhibitor（TKI） therapy significantly improved the prognosis and outcome of patients with chronic myeloid leukemia（CML）.Long-term therapy of TKI drugs was often accompanied with financial burden and the rise of chronic adverse effects.At present,the treatment-free remission（TFR） has been gradually regarded as the new ultimate aim to the patients with long-term CML.In clinical trials,the patients with the therapy of imatinib stopping TKI treatment after acquired deep molecular reaction still maintained remission.Here,the research progress on discontinuation of TKI therapy and how to better grasp the safety of drug withdrawal strategy are reviewed.However,the radical cure of CML needs more further research.